HC Wainwright Issues Pessimistic Forecast for CNTB Earnings

Key Points

• HC Wainwright has lowered its Q3 2025 earnings per share (EPS) estimate for Connect Biopharma to ($0.24), down from ($0.23).
• The consensus estimate for Connect Biopharma's current full-year earnings is ($0.22) per share, while Q4 2025 earnings are anticipated to be ($0.25) EPS.
• The stock is currently trading at $2.15, experiencing an 8.9% drop recently, with a 1-year price range between $0.51 and $2.86.

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB - Free Report) - Equities researchers at HC Wainwright reduced their Q3 2025 EPS estimates for Connect Biopharma in a research report issued on Wednesday, August 13th. HC Wainwright analyst B. Folkes now forecasts that the company will earn ($0.24) per share for the quarter, down from their previous forecast of ($0.23). HC Wainwright has a "Buy" rating and a $7.00 price target on the stock. The consensus estimate for Connect Biopharma's current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Connect Biopharma's Q4 2025 earnings at ($0.25) EPS, FY2027 earnings at ($0.89) EPS and FY2029 earnings at ($0.34) EPS.

Separately, Northland Capmk raised shares of Connect Biopharma to a "strong-buy" rating in a research report on Tuesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Strong Buy" and an average target price of $7.00.

Connect Biopharma Stock Down 5.5%

Shares of CNTB stock traded down $0.0990 during trading hours on Friday, reaching $1.7110. 139,131 shares of the stock traded hands, compared to its average volume of 114,261. Connect Biopharma has a 1-year low of $0.51 and a 1-year high of $2.86. The business has a fifty day moving average price of $1.57 and a 200 day moving average price of $1.06. The company has a quick ratio of 7.24, a current ratio of 7.24 and a debt-to-equity ratio of 0.01.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of CNTB. XTX Topco Ltd acquired a new stake in shares of Connect Biopharma in the 2nd quarter valued at approximately $29,000. Koa Wealth Management LLC bought a new position in shares of Connect Biopharma in the second quarter valued at $49,000. Finally, AlphaCore Capital LLC bought a new position in shares of Connect Biopharma in the second quarter valued at $78,000. Institutional investors own 58.72% of the company's stock.

About Connect Biopharma

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.